Test Price
1,200 AED✅ Home Collection Available
PML::RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative PCR Test in UAE | 1200 AED
Executive Summary & Core Metrics
Achieve 99.9% diagnostic sensitivity for acute promyelocytic leukaemia (APL) monitoring and treatment guidance with our ISO-certified quantitative PCR. Premium hospital-grade home collection, VIP mobile phlebotomy, and direct insurance billing verification are included.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity & 100% Specificity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) compliant qPCR.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
- Clinical Guidance: Complimentary Telephonic Post‑Test Clinical Result Interpretation by our DHA‑licensed team.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The PML::RARA qPCR test precisely quantifies the fusion transcript t(15;17)(q22;q12) that defines acute promyelocytic leukaemia (APL), enabling early diagnosis and disease monitoring. It guides targeted therapies (ATRA and arsenic trioxide) and detects minimal residual disease with unparalleled sensitivity.
| Parameter | Our PML::RARA qPCR | Closest Alternative (FISH / Cytogenetics) |
|---|---|---|
| Precision | Absolute quantification; sensitivity down to 1 abnormal cell in 104 | Qualitative or semi‑quantitative; 5-10% detection threshold |
| Methodology | Real‑Time Quantitative PCR (qPCR) with ISO‑certified standard curves | Fluorescence in‑situ Hybridisation (FISH) / Karyotyping |
| Turnaround Time | 2 business days (sample Mon/Wed/Fri by 9 AM → report Tue/Thu/Sat) | 5–10 calendar days |
| Clinical Utility | Diagnosis, remission assessment, MRD monitoring, resistance detection | Diagnosis only; limited for therapy monitoring |
Physician Insight & Safety Protocols
“This highly sensitive qPCR assay is a cornerstone for managing APL. However, results must always be correlated with the patient’s clinical picture, coagulation profile, and bone marrow morphology. A negative result does not exclude malignancy if clinical suspicion remains high.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Safety Exclusion Criteria & Emergency Red Flags
- The test is not indicated for individuals without clinical suspicion of APL or a known PML::RARA translocation.
- Do not submit if the patient is haemodynamically unstable or has active, uncontrolled bleeding.
- Pregnancy: Discuss risk‑benefit with your haematologist; genetic analysis requires specific counselling.
- Seek emergency care immediately if you experience: sudden bruising, petechiae, severe headache, shortness of breath, or any uncontrolled bleeding.
- A completed Genomics Clinical Information Requisition Form (Form 20) is mandatory. Incomplete forms will delay reporting.
Exclusion Criteria
Do not discontinue prescribed medication without consulting your doctor. The test should not be used as a sole screening tool in asymptomatic individuals without prior haematological evaluation.
Patient FAQ & Clinical Guidance
1. What is the PML::RARA gene rearrangement test?
This quantitative PCR test detects the fusion gene causing acute promyelocytic leukaemia, vital for diagnosis and monitoring treatment response. It specifically identifies the t(15;17) translocation and quantifies the fusion transcript level.
2. Why is this test performed?
It confirms acute promyelocytic leukaemia (APL), directs targeted therapy with ATRA and arsenic trioxide, and monitors remission or minimal residual disease during follow-up.
3. How should I prepare for the test?
No fasting is required. Provide a blood sample and a completed Form 20. Include a list of current medications, especially anticoagulants. The sample can be collected at home via our VIP Mobile Phlebotomy service.
4. How long does it take to get results?
Results are typically available within 2 business days. Samples must arrive by 9 AM on collection days (Monday, Wednesday, Friday) for reporting on the next working day.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
All procedures abide by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory is ISO 9001:2015 certified and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | PML::RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative PCR |
| Price (AED) | 1,200 AED |
| Turnaround Time | 2 business days (sample cut-off Mon/Wed/Fri 9 AM; reports next working day) |
| Sample Type / Matrix | Whole blood (5 mL in 2 Lavender Top EDTA tubes) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM to 11 PM |
| Methodology Used | Quantitative Real-Time PCR (qPCR) with ISO-certified standard curves |
| ICD-10-CM Code | C92.4 (Acute promyelocytic leukemia) |
| LOINC Code | 33696-8 (PML/RARA fusion transcript [Presence] in Blood by NAA with probe detection) |
| DHA Facility License & Laboratory Address Invariants | DHA Facility License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians